尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶治疗晚期口腔癌的短期疗效观察
Clinical study on Nimotuzumab combined with Docetaxel-Cisplatin-Fluorouracil regimen in the treatment of advanced oral carcinoma
作者：顾倩平 孟箭 孟庆飞 张杰 李志萍
Author：Gu Qianping, Meng Jian, Meng Qingfei, Zhang Jie, Li Zhiping.
收稿日期：2011-06-04 年卷（期）页码：2011,38(6):652-655
期刊名称：国际口腔医学杂志
Journal Name：International Journal of Stomatology
关键字：尼妥珠单抗,口腔癌,多西他赛,顺铂,氟尿嘧啶,化学治疗,
Key words：
Nimotuzumab,oral carcinoma,Docetaxel,Cisplatin,Fluorouracil,chemotherapy
,
基金项目：
徐州市社会发展科技基金资助项目（XZZD1017）
中文摘要
目的 观察尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶（DCF）治疗晚期口腔癌的短期疗效及不良反应。方法 9 例晚期口腔癌患者采用尼妥珠单抗联合DCF 化学治疗方案：尼妥珠单抗200 mg，每周1 次，连用6 个周期；多西他赛75 mg·m-2，第1 天，静脉滴注；顺铂75 mg·m-2，第1 天，静脉滴注；氟尿嘧啶750 mg·m-2，第1～5 天，每天持续静脉输注8 h。21 天为l 周期。结果 对9 例患者化学治疗后进行短期疗效评价示，有效率为88.89％，疾病控制率为100％。本研究化学治疗主要的不良反应有白细胞减少、恶心呕吐、脱发、电解质紊乱等。结论 尼妥珠单抗联合DCF 方案治疗晚期口腔癌短期内安全有效，可扩大样本量进行深入研究。
英文摘要
ObjectiveTo evaluate the efficacy and toxicity of Docetaxel-Cisplatin-Fluorouracil（DCF） regimen and Nimotuzumab on treating advanced oral carcinoma. Methods Nine patients with advanced oral carcinoma were collected and treated with the methods of DCF and Nimotuzumab in this study． All patients were given as follows: Nimotuzumab with 200 mg intravenous drip weekly for 6 weeks; Docetaxel and Cisplatin with 75 mg·m-2each only used on the first day; Fluorouracil with 750 mg·m-2infused continually for 8 hours from 1st to 5th day; the total cycle was 21 days. Results All nine patients were evaluated for objective response. The response rate was 88.89％. The disease control rate was 100％. The major side effects were as follows: Bone marrow suppression, nausea, vomiting, alopecia and so on. Conclusion The method of Nimotuzumab combining with DCF regimen was effective and safe on the treatment of advanced oral carcinoma.
下一条：下颌功能性正中偏移与上颌第一磨牙牙龈萎缩的关系
【关闭】
